FcRn Antikörper

Produktnummer ABIN1774762

Produktdetails anti-FcRn Antikörper

Highlights:

• Hochwertiger FcRn-Antikörper (Klon ADM31) für den Nachweis von FcRn.
• Hochspezifisch für humanes FcRn, blockt die Bindung von humanem Serumalbumin.
• PBS-only, preservative free.
• 15 PubMed-Referenzen für diesen FcRn-Antikörper verfügbar.

Target: FcRn (IgG receptor FcRn (FcRn))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser FcRn Antikörper ist unkonjugiert

Applikation: ELISA, Immunofluorescence (IF), Flow Cytometry (FACS), Cell-ELISA (cELISA), Functional Studies (Func)

Produktmerkmale: based on recognition of the complete native protein expressed on transfected mammalian cells

Aufreinigung: Purified, Protein G

Immunogen: hFcRn

Klon: ADM31

Isotyp: IgG2b lambda

Produktspezifische Information:

Wofür kann der FcRn-Antikörper ABIN1774762 / ADM31-Antikörper verwendet werden? Dieser monoklonale Maus-Anti-FcRn-Antikörper ist unkonjugiert und eignet sich für den Nachweis von FcRn (Fc-Rezeptor) in menschlichen Proben. Der FcRn-Antikörper ist für Zell-ELISA, ELISA, FACS und IF validiert.

Welche Validierungsdaten sind für diesen FcRn-Antikörper / ADM31-Antikörper verfügbar? Es sind 6 Bilder für FACS und andere Anwendungen verfügbar. Das Produkt wird in 15 PubMed-Publikationen zitiert. Nutzen Sie unser hochwertiges Produkt zum zuverlässigen Nachweis des Fc-Rezeptors.

Der MHC-Klasse-I-ähnliche Fc-Rezeptor (FcRn) fungiert als intrazellulärer Trafficking-Rezeptor, der in einzigartiger Weise für die Verlängerung der Serum-Halbwertszeit von Antikörpern der IgG-Subklasse verantwortlich ist und ihre Passage durch zelluläre Barrieren erleichtert. Auf diese Weise wirkt sich FcRn auf verschiedene Aspekte der Antikörperbiologie und -pathobiologie aus. Seine entscheidende Rolle bei der Regulierung der IgG-Pharmakokinetik wurde bei der Entwicklung von therapeutischen Antikörpern und damit verbundenen biologischen Behandlungen genutzt. Darüber hinaus ist FcRn am Transport von Serumalbumin beteiligt und trägt so zu den verbesserten pharmakokinetischen Eigenschaften von Albumin-konjugierten Therapien bei. Der Mangel an zuverlässigen serologischen Instrumenten, die auf menschliches FcRn abzielen, hat jedoch das Verständnis seiner Funktionen und potenziellen therapeutischen Anwendungen eingeschränkt.

Anwendungsinformationen

Applikationshinweise:

• Flow cytometry: 1.2 μg/10^6 cells
• ELISA: 1:200 - 1:400
• CELISA: 1:200 - 1:400

For each application a titration should be performed to determine the optimal concentration.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS pH 7.2

Handhabung: avoid repeated freezing and thawing

Lagerung: 4 °C

Referenzen für anti-FcRn Antikörper (ABIN1774762)

Gjølberg, Frick, Mester, Foss, Grevys, Høydahl, Jørstad, Schlothauer, Sandlie, Moe, Andersen: "Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life." in: Communications biology, Vol. 5, Issue 1, pp. 832, (2022) (PubMed).

Cines, Zaitsev, Rauova, Rux, Stepanova, Krishnaswamy, Sarkar, Kowalska, Zhao, Mast, Blumberg, McCrae, Poncz, Hubbard, Pyzik, Blumberg: "FcRn augments induction of tissue factor activity by IgG-containing immune complexes." in: Blood, Vol. 135, Issue 23, pp. 2085-2093, (2021) (PubMed).

Hubbard, Pyzik, Rath, Kozicky, Sand, Gandhi, Grevys, Foss, Menzies, Glickman, Fiebiger, Roopenian, Sandlie, Andersen, Sly, Baker, Blumberg: "FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity." in: The Journal of experimental medicine, Vol. 217, Issue 10, (2021) (PubMed).

Bern, Nilsen, Ferrarese, Sand, Gjølberg, Lode, Davidson, Camire, Bækkevold, Foss, Grevys, Dalhus, Wilson, Høydahl, Christianson, Roopenian, Schlothauer, Michaelsen, Moe, Lombardi, Pinotti, Sandlie et al.: "An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. ..." in: Science translational medicine, Vol. 12, Issue 565, (2021) (PubMed).

Casulleras, Flores-Costa, Duran-Güell, Alcaraz-Quiles, Sanz, Titos, López-Vicario, Fernández, Horrillo, Costa, de la Grange, Moreau, Arroyo, Clària: "Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis." in: Science translational medicine, Vol. 12, Issue 566, (2021) (PubMed).

Blumberg, Humphries, Jones, Pearce, Holgate, Hearn, Cheung, Mahmood, Del Tito, Graydon, Stolz, Bitonti, Purohit, de Graaf, Kacena, Andersen, Christianson, Roopenian, Hubbard, Gandhi, Lasseter, Pyzik et al.: "Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. ..." in: Science advances, Vol. 5, Issue 12, pp. eaax9586, (2020) (PubMed).

Chung, Nguyen, Lin, Lafrance-Vanasse, Scales, Lin, Deng, Williams, Sperinde, Li, Zheng, Sukumaran, Tesar, Ernst, Fischer, Lazar, Prabhu, Song: "An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans." in: mAbs, Vol. 11, Issue 5, pp. 942-955, (2019) (PubMed).

Swiercz, Mo, Khare, Schneider, Ober, Ward: "Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption." in: Oncotarget, Vol. 8, Issue 2, pp. 3528-3541, (2018) (PubMed).

Pyzik, Rath, Kuo, Win, Baker, Hubbard, Grenha, Gandhi, Krämer, Mezo, Taylor, McDonnell, Nienaber, Andersen, Mizoguchi, Blumberg, Purohit, Jones, Christianson, Lencer, Sandlie, Kaplowitz, Roopenian et al.: "Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. ..." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, Issue 14, pp. E2862-E2871, (2018) (PubMed).

Grevys, Nilsen, Sand, Daba, Øynebråten, Bern, McAdam, Foss, Schlothauer, Michaelsen, Christianson, Roopenian, Blumberg, Sandlie, Andersen: "A human endothelial cell-based recycling assay for screening of FcRn targeted molecules." in: Nature communications, Vol. 9, Issue 1, pp. 621, (2018) (PubMed).

Roopenian, Christianson, Proetzel, Sproule: "Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies." in: Methods in molecular biology (Clifton, N.J.), Vol. 1438, pp. 103-14, (2017) (PubMed).

Foss, Grevys, Sand, Bern, Blundell, Michaelsen, Pleass, Sandlie, Andersen: "Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization." in: Journal of controlled release : official journal of the Controlled Release Society, Vol. 223, pp. 42-52, (2016) (PubMed).

Christianson, Sun, Akilesh, Pesavento, Proetzel, Roopenian: "Monoclonal antibodies directed against human FcRn and their applications." in: mAbs, Vol. 4, Issue 2, pp. 208-16, (2014) (PubMed).

Powner, McKenzie, Christianson, Roopenian, Fruttiger: "Expression of neonatal Fc receptor in the eye." in: Investigative ophthalmology & visual science, Vol. 55, Issue 3, pp. 1607-15, (2014) (PubMed).

Sand, Dalhus, Christianson, Bern, Foss, Cameron, Sleep, Bjørås, Roopenian, Sandlie, Andersen: "Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies." in: The Journal of biological chemistry, Vol. 289, Issue 24, pp. 17228-39, (2014) (PubMed).

Details zu FcRn

Target: FcRn (IgG receptor FcRn (FcRn))

Abstract: FcRn Produkte

Synonyme: FCRN antikoerper, alpha-chain antikoerper, FcRn antikoerper, Fc fragment of IgG receptor and transporter antikoerper, Fc receptor, IgG, alpha chain transporter antikoerper, FCGRT antikoerper, Fcgrt antikoerper

Hintergrund: The MHC class I-like Fc receptor (FcRn) is an intracellular trafficking Fc receptor that is uniquely responsible for the extended serum half-life of antibodies of the IgG subclass and their ability to transport across cellular barriers. By performing these functions, FcRn affects numerous facets of antibody biology and pathobiology. Its critical role in controlling IgG pharmacokinetics has been leveraged for the design of therapeutic antibodies and related biologics. FcRn also traffics serum albumin and is responsible for the enhanced pharmacokinetic properties of albumin-conjugated therapeutics.
Synonyms: IgG receptor FcRn large subunit p51, Neonatal Fc receptor, FCGRT

UniProt: P55899

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process